There are a number of drugs prescribed to people with alcohol use disorders. In the United States, the use of Vivitrol (naltrexone) has become quite common for the treatment of both opioid use disorder and alcoholism. With some patients, Vivitrol has been found to reduce their craving for alcohol. Used in conjunction with antabuse, which makes someone ill if they consume alcohol—those recovering from alcohol dependence and/or addiction can have a better chance of abstaining from booze in early recovery.
Addiction recovery is no easy task, and if there is something that can help reduce the risk of relapse, it is often advised to utilize such a resource. Researchers continue to develop new drugs to help mitigate the urges to drink, something that is particularly useful when it comes to alcohol. Unlike many other commonly abused drugs, alcohol can be found in grocery stores or the corner market. Magazines, television and the Internet bombards people with advertisements portraying only the good side of alcohol, they fail to express the slippery slope that can accompany continued alcohol use.
With all medications, extensive research is supposed to be conducted—followed by clinical trials to determine the drug’s efficacy. This is to insure that the drug works and figure out which side effects patients may expect. Unfortunately, the aforementioned steps are not always taken, leading to patients being given ineffective drugs. Such may be the case with a medication prescribed in Europe to reduce cravings for alcohol.
In 2013, nalmefene, sold under the brand name Selincro, was approved in Europe to reduce drinking. However, a group of researchers identified some issues with the clinical trials that led to the drug’s approval, ScienceDaily reports. The findings were published in the journal Addiction.
After analyzing the clinical trials conducted on nalmefene, the researchers from the University of Stirling found that it was impossible to determine how effective that drug was for those with heavy drinking disorders, according to the article. At best, the drug would reduce a patient’s average alcohol consumption by one beverage.
“It’s vitally important that we know that prescribed drugs are effective in treating the intended problem,” said Dr Niamh Fitzgerald, a pharmacist and Lecturer in Alcohol Studies at the University’s Institute for Social Marketing. “In this case, we found problems with the registration, design, analysis and reporting of these clinical trials which did not prevent the drug being licensed or recommended for use.”
It is worth noting that after the drug Selincro was approved it was recommended by the UK National Institute for Health and Care Excellence (NICE). It would seem that they may need to evaluate such a recommendation with these new findings.
Alcohol Use Disorder Recovery
Those who have unhealthy relationships with alcohol put their life at serious risk. Heavy use can lead to an alcohol use disorder which, if left untreated, inhibits one’s ability to function and can lead to a number of serious health conditions—some of which can be fatal.
At Synergy Group Services, we specialize in treating alcoholism, we can help you or a loved one break the cycle of addiction and give you the tools necessary for sustaining long term abstinence from all mind altering substances.